Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 28, 2021 at 04:18 am EDT
Share
Wuhan Hiteck Biological Pharma Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 392.37 million compared to CNY 348.59 million a year ago. Revenue was CNY 392.37 million compared to CNY 348.59 million a year ago. Net income was CNY 18.64 million compared to net loss of CNY 10.53 million a year ago. Basic earnings per share from continuing operations was CNY 0.18 compared to basic loss per share from continuing operations of CNY 0.1 a year ago. Diluted earnings per share from continuing operations was CNY 0.18 compared to diluted loss per share from continuing operations of CNY 0.1 a year ago.
Wuhan Hiteck Biological Pharma Co., Ltd. is a China-based pharmaceutical company. The Company is mainly engaged in research and development, manufacture and sales of biological products, thrombin and other chemical products. The Company's main products include mouse nerve growth factor freeze-dried powder for injection, Anti-HBV transfer factor freeze-dried powder for injection, thrombin freeze-dried powder, levofloxacin mesylate for injection, defibrase for injection, pentoxifylline for injection, mecobalamin injection, ozagrel sodium for injection and others. The Company's main brands include Jinlujie, Aogantai, Haimibao, Haotetong and others.